Search - tctmd.com

Displaying 81 - 100 of 125

Sort: Relevancy | Date

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Yael L. Maxwell

December 12, 2019

Presentation TCT 2019

LP(a): Not So Little Anymore

Presenter: Roberta Rossini

September 26, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2019

Shelley Wood

May 01, 2019

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

Could PET Imaging Be the ‘Game Changer’ for Detecting and Predicting Bioprosthetic Valve Degeneration?

Michael O'Riordan

March 13, 2019

News Daily News

Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds

Yael L. Maxwell

January 25, 2019

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Daily News

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Caitlin E. Cox

July 10, 2018

News Daily News

Lp(a) Might Not Be Good at Predicting Incident CVD in Low-Risk Women

Yael L. Maxwell

July 09, 2018

News Daily News

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

Yael L. Maxwell

June 25, 2018

News Conference News EAS 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Yael L. Maxwell

May 14, 2018

News Conference News EAS 2018

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Yael L. Maxwell

May 08, 2018

Advertisement

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

LP(a): Not So Little Anymore

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

TCTMD’s Top 10 Most Popular Stories for June 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

TCTMD’s Top 10 Most Popular Stories for April 2019

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Could PET Imaging Be the ‘Game Changer’ for Detecting and Predicting Bioprosthetic Valve Degeneration?

Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Lp(a) Might Not Be Good at Predicting Incident CVD in Low-Risk Women

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content